US$ 25.05
sglt2 inhibitors and glp-1 receptor agonists inhibitors: a couple at last? Effect of combination treatment with
Description
These differences matter clinically: larger average weight loss translates into bigger improvements in blood pressure, glycemic measures, sleep apnea metrics, mobility, and quality of life for many patients

This review aims to discuss the mechanisms, pleiotropic effects, and therapeutic potential of GLP-1, DPP-4, and SGLT2, with a particular focus on their cardiorenal benefits beyond glycemic control

Nature website
Until recently, only liraglutide was FDA-approved for weight-loss in non-diabetic patients under the trade name Saxenda

Cardiovasc Saf Trials all New Diabetes Mellitus Drugs

W., Lingvay, I., Reed, J., De La Rosa, R., Rose, L., Sugimoto, D., Araki, E., Chu, P
